Overcoming Barriers to Prescribing First-Line Medications for CRM Conditions

EP: 1.The Impact of CRM Diseases in the US: Burden, Prevalence, and Obesity

EP: 2.Strategies for Prevention and Screening of CRM Conditions

EP: 3.The Link Between Obesity and CRM Conditions

EP: 4.Challenges in Managing Co-Morbid CRM Conditions

EP: 5.Contemporary Guidelines for CRM Conditions

EP: 6.Reasons for Low Adherence to Guidelines for CRM Conditions

Now Viewing

EP: 7.Overcoming Barriers to Prescribing First-Line Medications for CRM Conditions

EP: 8.Educational Initiatives to Enhance Guideline Adherence in CRM

EP: 9.Addressing Gaps in CKD, T2D, and CVD Guidelines

EP: 10.Care Coordination for High-Risk CRM Patients

EP: 11.Takeaways from the UH CINEMA Program

EP: 12.Exploring the Kidney-CHAMP Study

EP: 13.Insights from the COORDINATE-Diabetes Trial

EP: 14.Coordinating Initiatives to Enhance CRM Care

EP: 15.Implementing CRM Learnings and Utilization of Telehealth

Video content above is prompted by the following:

• Despite being approved for first-line treatment, medications such as SGLT2 inhibitors and GLP1-receptor agonists are not frequently prescribed to qualified patients. What has been effective in your practice to get these first line medications covered in the patient population who needs it the most?

This activity is supported by Boehringer Ingelheim Pharmaceuticals Inc. and Eli Lilly and Company who provided financial support for this program.